Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers
H. Y. Khan, M. Nagasaka, A. Aboukameel, O. Alkhalili, M. H. Uddin, S. Bannoura, Y. Mzannar, A. Ibrahim, E. Beal, M. Tobon, S. Kim, R. Beydoun, E. Baloglu, W. Senapedis, B. Elrayes, , A. S. Azmi
This study shows that combining KRASG12C inhibitors with PAK4 inhibitor KPT9274 enhances antitumor activity and survival in preclinical models of KRASG12C mutant pancreatic and lung cancers.
bioRxiv · Mar 27, 2023Cancer Biology